Skip to main content

OB GYN

Clear, concise results with expert guidance, interpretation and personal counselling.

Unilabs provides a comprehensive range of diagnostic, carrier and predictive genetic testing.

Predictive genetic testing for the risk of breast and ovarian cancer
According to the American Cancer Society, about 5 to 10% of all cancers are thought to be related to gene mutations that are inherited. Individuals with such mutations have a higher risk of developing a certain type or types of cancer. Our tests can look for many inherited gene mutations. This type of testing is recommended when certain types of cancer run in a family and a gene mutation is suspected.

Genetic testing for diagnosing and treating breast and ovary cancer 
Genetic testing can help you confirm a diagnosis, determine the type of tumour, determine which treatment will be most effective as well as monitor the patient’s treatment and remission.

Genetic testing for infertility 
We help you to identify genetic causes of infertility to facilitate your patients’ informed decisions and family planning.

Prenatal testing 
Our prenatal tests are useful for detecting changes in a foetus’s genes or chromosomes before birth. This type of testing is offered during pregnancy. These tests help you estimate whether there is an increased risk that the baby will have a genetic or chromosomal disorder. We can help you reduce your patient’s uncertainty or help them make decisions about a pregnancy.
 

OB GYN
Predictive Genetic testing for Breast, Ovarian and Onco-risk

A selection of genetics panels for OB-GYN:

Cancer

FAMILIAL BREAST/OVARIAN CANCER (BRCA1 and BRCA2 NGS panel, including CNV analysis)

This panel includes sequencing and copy number variation (CNV) analysis of BRCA1 and BRCA2 genes, for the detection of germline mutations. It is aimed for the diagnosis of familial breast/ovarian cancer to allow guided treatment and clinical management as well as genetic counselling for the patient and at-risk relatives.

It should be considered in patients with early onset (< 50yo) of breast cancer, more than one primary breast cancer, in ovarian cancer and multiple affected relatives.

TAT: 30 days  |  Sample: Blood (3mL EDTA) or extracted DNA (2µg)

 

Breast cancer (NGS panel for 26 genes, including CNV analysis)

This panel includes sequencing and CNV analysis of 26 genes known to cause breast cancer, for the detection of germline mutations. It is used in cases were the clinical presentation is not suggestive of BRCA1/2 mutations, if the purpose is to expand the scope of the genes tested to increase the probability of finding the causative mutation, or if BRCA1/2 testing was negative. It is aimed for the diagnosis of familial breast cancer to allow guided treatment and clinical management as well as genetic counselling for the patient and at-risk relatives.

TAT: 45 days  |  Sample: Blood (3mL EDTA) or extracted DNA (2µg)

 

OncoRisk Expanded (NGS panel for 89 genes, including CNVs analysis)

This panel includes sequencing and CNV analysis of 89 genes associated with cancer, for the detection of germline mutations. This panel is used in cases were the type of cancers, in the patient or other relatives, and the family history, does not point to a specific hereditary cancer syndrome, and a broader approach may increase the chance of reaching a genetic diagnosis.

TAT: 45 days  |  Sample: Blood (3mL EDTA) or extracted DNA (2µg)

Carrier Testing

Carrier screening premium test

This is an expanded carrier screening test for any couple planning their pregnancy. It tests the most common genetic diseases, that may affect the offspring of healthy parents, even with no family history of genetic disorders. The aim is to detect if any or both members of the couple are carriers of a genetic mutation to evaluate if there is an increased risk of having a child with one of the genetic disorders tested. The panel includes sequencing analysis of 101 genes for recessive diseases as well as fragile X syndrome and spinal muscular atrophy.

TAT: 45 days  |  Sample: Blood (3mL EDTA) or extracted DNA (2µg)

 

 

Infertility

Premature ovarian failure (NGS panel for 48 genes)

Female infertility (NGS panel for 132 genes)

Male infertility (NGS panel for 116 genes)

Spermatogenic failure (NGS panel for 21 genes)

Infertility may have different causes. Depending on the clinical presentation, one or more of these four NGS panels can be used in couples with infertility to understand the aetiology. Beyond understanding the cause, it will help define the clinical management and treatment options.

TAT: 45 days  |  Sample: Blood (3mL EDTA) or extracted DNA (2µg)

Prenatal Testing

(We also offer non-invasive prenatal testing)

NGC PANELS FOR PRENATAL DIAGNOSIS:

FOetal hydrops (WHOLE EXOME SEQUENCING based NGS panel for 66 genes); 

Skeletal dysplasia (NGS panel for 6 genes, PRENATAL DIAGNOSIS); 

Noonan syndrome and other genetically related syndromes
(NGS panel for 9 genes, PND)

During pregnancy, specific sonographic alterations may be detected, raising the possibility of a genetic disorder in the foetus. These panels were designed for distinct clinical presentations, namely foetal hydrops (foetal hydrops panel), skeletal anomalies, e.g. short long bones (Skeletal dysplasia panel) and nuchal translucence above the 99th centile (Noonan syndrome and other genetically related syndromes panel). Reaching a genetic diagnosis will guide treatment and clinical management options, and provide information regarding the prognosis of the foetus affected with the detected disorder, helping physicians and parents in the management of the pregnancy. Additionally, it will allow proper genetic counselling to the parents.

TAT: 21 days  |  Sample: Amniotic fluid (>5mL), chorionic villus (>30mg), cell culture (2 x T25 confluent) or extracted DNA (1µg)

 

Array CGH for prenatal diagnosis

Chromosomal microarray analysis is recommended in the aetiological investigation of foetuses with structural abnormalities detected in the foetal sonogram, foetuses with nuchal translucency above the 99th centile, and foetuses with chromosome rearrangements detected by conventional cytogenetics. It aims to detect chromosomal imbalances (CNVs) that may explain the detected foetal abnormalities. A genetic diagnosis will guide the clinical management of the pregnancy, provide information regarding the prognosis and allow a specific genetic counselling.

TAT: 10 days  |  Sample: Amniotic fluid (>5mL), chorionic villus (>30mg), cell culture (2 x T25 confluent) or extracted DNA (1µg)